What does the evidence actually show about every-8-week dosing?
The strongest evidence comes from a 32-week extension of a long-term study (ADjoin) that directly compared lebrikizumab given every 8 weeks versus every 4 weeks in patients who had already responded to treatment [1]. At the end of the extension, 79% of the every-8-week group maintained at least a 75% improvement in eczema severity (EASI 75), while 86% of the every-4-week group did [1]. This means that for most patients, spacing out injections to every 8 weeks did not lead to a major loss of skin clearance, though the every-4-week group did slightly better.
The same study also looked at complete or almost-complete clearance (IGA 0/1, meaning clear or almost clear skin). Here, 62% of the every-8-week group achieved this, versus 73% in the every-4-week group [1]. So while every-8-week dosing is effective for many, it is not quite as potent as monthly dosing for the best possible outcome. Importantly, the study was not designed to prove that the two schedules are equivalent, so the small difference could be due to chance or patient differences [1].
How does this translate into better adherence?
The practical benefit is straightforward: fewer injections means less burden on the patient. If a patient only needs a shot every 8 weeks instead of every 4 weeks, they have half as many appointments or self-injections to remember, schedule, and pay for. This is a major factor in chronic conditions like atopic dermatitis, where long-term treatment is often needed. The study's authors explicitly note that the durable response with every-8-week dosing supports the idea of a 'disease-modifying effect,' meaning the drug may keep working even with less frequent maintenance [1].
It's also worth noting that the patients in this study had already responded well to 16 weeks of initial treatment, so every-8-week dosing is not for everyone from the start—it's a maintenance strategy for those who have already achieved good control [1]. This is a key caveat: the evidence supports every-8-week dosing as a maintenance option, not as a starting dose.
Why is IL-13 such a good target for this approach?
IL-13 is a central driver of the type-2 inflammation that causes atopic dermatitis—it's overproduced in the skin, disrupts the skin barrier, and triggers itch [2][4]. By blocking IL-13, lebrikizumab directly targets this core pathway. The fact that a drug can be given every 8 weeks and still maintain response suggests that IL-13 blockade has a long-lasting effect on the disease process, not just a temporary symptom patch [1]. This is consistent with the idea that sustained suppression of IL-13 can 'reset' the skin's immune environment, as supported by the durable responses seen in long-term studies [3].
While other targets like TWEAK are also being explored, IL-13 remains the most validated target in human trials [5]. The evidence here, spanning multiple studies, consistently shows that IL-13 blockade is effective and safe, making it a reliable option for patients who need long-term control [1][3].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 1 from 2024 or later, 3 in Q1 journals, collectively cited 81 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 34 papers retrieved from a database of over 500 million.
Sources used in this answer
Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis
In a 32-week extension of the ADjoin study, 79% of patients on every-8-week lebrikizumab maintained EASI 75 (≥75% improvement) versus 86% on every-4-week, and 62% achieved IGA 0/1 (clear/almost clear) versus 73%, with no serious adverse events.
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis
This review highlights IL-13 as a crucial cytokine in atopic dermatitis, driving type-2 inflammation, skin barrier disruption, and itch, and notes that targeting IL-13 is efficacious and safe.
Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis
Long-term extension data (ADjoin) show that lebrikizumab maintains efficacy in skin and itch outcomes through 2 years with both monthly and every-2-week dosing, with no new safety signals.
The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis
This review confirms that IL-4 and IL-13 are central to type-2 inflammation in atopic dermatitis, and that blocking these cytokines is a key therapeutic strategy.
TNF‐like weak inducer of apoptosis inhibition is comparable to IL‐13 blockade in ameliorating atopic dermatitis inflammation
In a mouse model, blocking TWEAK reduced atopic dermatitis inflammation to a similar extent as blocking IL-13, suggesting TWEAK as a potential future target, but this is not yet validated in humans.